Purpose of the Test
- Evaluating the effectiveness of chemotherapy or immunotherapy.
- Early detection of potential relapse.
- Confirming molecular-level remission status.
Book Myeloma MRD NGS Test in Saudi Arabia | Lahalak Medical Platform
A high-sensitivity test using Next-Generation Sequencing (NGS) to detect minimal residual cancerous cells in bone marrow, providing critical data for monitoring treatment efficacy and predicting long-term remission in myeloma patients.
Scientific name: Plasma Cell Myeloma Minimal Residual Disease (MRD) by NGS
An advanced diagnostic tool for multiple myeloma patients. It detects residual cancer cells at a molecular level, allowing doctors to refine treatment strategies and monitor for potential relapse with high precision.
Service type
Specialized laboratory test
Duration
30-45 minutes
Fasting
Fasting is not required
Included Services
- Bone marrow aspiration/biopsy
- Next-Generation Sequencing (NGS) analysis
- Detailed medical report
Medical Service Information
Why NGS Technology?
- Up to 100 times more sensitive than traditional flow cytometry.
- Can detect one cancer cell among a million healthy cells.
- Provides a precise genetic clone ID for future monitoring.
Target Groups
- Multiple Myeloma patients post-stem cell transplant.
- Patients who have achieved clinical Complete Response (CR).
- Cases requiring data to decide on treatment maintenance or cessation.
Conditions & Notices
- Should be performed after specific treatment cycles
- Requires treating physician's referral
Medical services you might also like
